Drug interaction study launches: will BV100 change how polymyxin b works?

NCT ID NCT07580586

Recruiting now Knowledge-focused Sponsor: BioVersys SAS Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing whether a new drug called BV100 changes how the body processes the antibiotic polymyxin B. Sixteen healthy adults will receive polymyxin B alone and then again with BV100 to compare drug levels. The goal is not to treat disease but to gather safety and dosing information for future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

BV100 and polymyxin B

What this could lead to

If successful, this could help doctors adjust polymyxin B doses when given with BV100, potentially improving safety and effectiveness in future patients.

What could go wrong

This is a very early, small study in healthy people, not patients. It only measures drug levels, not treatment outcomes, so results may not apply to sick individuals.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY ADULT PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY ADULT PARTICIPANTS

Contacts and locations

Show contact details

Locations

Medical University of Vienna
RECRUITING

Vienna, 1090, Austria

Contact Phone: •••-•••-••••